Aging
Conditions
Keywords
ageing, locus coeruleus, noradrenaline, cognition, memory, MRI, pupillometry
Brief summary
This research proposes to investigate physiological and cognitive markers of locus coeruleus (LC) neuronal integrity and function in cognitively-healthy participants over 60 years old. The locus coeruleus is a brainstem nucleus, sole source of noradrenaline for the brain. Tau pathology appears in neurons of this nucleus, which may induce initial cognitive changes. The study aims at relating locus coeruleus markers, assessed with MRI and eye-tracking techniques, with cognitive function.
Detailed description
The LC is a small brainstem nucleus, sole source of noradrenaline (NA) to the brain. NA is involved in the physiological arousal response: LC neuronal activity is closely related with pupil dilation, and pupil size is now considered a reliable and easy-access biomarker of LC function. NA-dependent cognitive functions include attention, flexibility and memory, which are selectively impaired with age. Accordingly, LC-NA system dysfunction may occur and contribute to initial cognitive changes during old age. The study will assess, in cognitively-healthy older volunteers from the INSPIRE cohort (n=100, over 60 years old), MRI and pupillometry markers of LC integrity, LC-forebrain connectivity and LC activity. We aim at investigating the relationship between LC biomarkers and cognitive status. Four experimental visits will be conducted by each participant, every 6 months over an 18-month period. Visits V1 and V4 will include MRI, eye-tracking and detailed cognitive exams. Visits V2 and V3 will include a detailed cognitive exam.
Interventions
OTHERMRI
MRI examinations will be conducted on the 3T MRI technical platform. During the MRI examination, images reflecting the integrity of the LC (quantification of neuromelanin as well as its functional connections with the different brain regions (resting functional MRI) will be acquired. High-resolution T1 and T2 weighted images of the the entire brain will also be acquired for the volumetry of cerebral areas.
OTHEReye-tracking
Eye tracking examinations will be conducted using an EyeBrain medical device (class IIa) developed by Suricog. This eye tracker will be installed in a box, in an experimental room. The eye tracker is combined with a computer to present visual cognitive tasks. Pupillary dilation/constriction measurements will be acquired at rest (when fixing a cross presented on the screen) and during the performance of different cognitive tasks (exploration and processing of scenes visuals, reading texts, making saccades or anti-saccades when presenting visual targets). These pupillary measurements will then be linked to the memorization of the stimuli presented, this recognition being tested at the end of the exam.
OTHERcognitive exams
Cognitive measures will be acquired during an evaluation session through interactive cognitive exercises. These exercises are developed using tools offered by Covirtua Healthcare (Covirtua Cognition software). Some exercises will test cognitive systems a priori dependent on NA release (episodic memory, working memory, selective attention, selective inhibition, planning) and other a priori independent of NA (semantic memory: categorization, naming).
Sponsors
University Hospital, Toulouse
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* INSPIRE cohort participant * Mini-Mental State Examination score ≥ 27 on 30 * Access to a web connection from participant's or relative's home and regular use of web surfing * Signature of the informed consent * Affiliated to a social security scheme
Exclusion criteria
* Any contra-indications to MRI exam * Ophthalmic pathology impacting eye-tracking measures * Neurological or psychiatric pathology * Person under guardianship or curatorship Contraindications to MRI examination: * Pacemaker or cardiac defibrillator * Implanted material activated by an electrical, magnetic or mechanical system * Haemostatic clips for intracerebral aneurysms or carotid arteries * Orthopedic implants * Claustrophobia Ophthalmological pathologies impacting eye tracking measurements: * Glaucoma * Age-related macular degeneration * Unoperated cataract
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Imaging contrast between the LC nucleus and the pontine tegmentum region | 18 months | The outcome will be measured with brainstem anatomical MRI (no unit) at visits V1 (immediately after inclusion) and V4 (18 months after inclusion). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Amplitude of the phasic pupil response during completion of cognitive tasks | 18 months | It will be assessed with eye-tracking (in millimeter) at visits V1 (immediately after inclusion) and V4 (18 months after inclusion). |
| Latency of saccadic eye movements during completion of cognitive tasks | 18 months | It will be assessed with eye-tracking (in milliseconds) at visits V1 (immediately after inclusion) and V4 (18 months after inclusion). |
| Z-score of the LC-forebrain connectivity at rest | 18 months | It will be assessed with resting-state functional MRI (no unit) at visits V1 (immediately after inclusion) and V4 (18 months after inclusion). |
| Composite cognitive (executive and memory) score | 18 months | It will be assessed (no unit) at visits V1 (immediately after inclusion), V2 (6 months after inclusion), V3 (12 months after inclusion) and V4 (18 months after inclusion). |
| Levels of blood phospho-Tau | 18 months | It will be assessed by single-molecule array (Simoa) technology (picogram/ml) |
| Amplitude of saccadic eye movements during completion of cognitive tasks | 18 months | It will be assessed with eye-tracking (in millimeter) at visits V1 (immediately after inclusion) and V4 (18 months after inclusion). |
Countries
France
Contacts
Primary ContactPierre PAYOUX, MD
Backup ContactFlorence REMY, PhD
Outcome results
None listed